Economic Considerations for Complex Mixture Drugs

Abstract

This chapter focuses on naturally derived complex drug products from an economic and regulatory point of view. Key stakeholders in the healthcare industry (e.g., physicians and payers) have been using pharmacoeconomic evaluations to make critical decisions, such as those pertaining to prescription and reimbursement coverage. The cost-effectiveness analytical tools used to conduct these evaluations are herein introduced. The pharmacoeconomic studies on commercially available naturally derived complex drug products are reviewed prior to discussion of the future prospect of these products.